The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Gain on disposal of fixed assets | 0 | - |
| Impairment of intangible assets | 0 | 0 |
| Impairment of operating lease right-of-use assets | 0 | 0 |
| Inventory write-downs | 0 | 0 |
| Net loss | -14,217 | -43,008 |
| Depreciation and amortization | 1,395 | 2,952 |
| Unrealized gain on derivative liability | 1,059 | 2,794 |
| Loss on debt extinguishment | 0 | -4,654 |
| Non-cash interest expense | 0 | 7,325 |
| Amortization of debt discount and issuance costs on notes payable | 2,192 | 7,723 |
| Share-based compensation expense | -1,603 | 3,851 |
| Net accretion of premium on short-term investments | -89 | -195 |
| Accounts receivable | -64 | -822 |
| Inventory | 2,002 | 3,796 |
| Other current and non-current assets | 1,960 | 210 |
| Accounts payable | -225 | 432 |
| Accrued liabilities | 1,362 | -275 |
| Contract liabilities and other current liabilities | 482 | -450 |
| Operating lease liabilities | -1,091 | -1,097 |
| Other long-term liabilities | -63 | -197 |
| Unrealized gain on warrant liability | -326 | 2,564 |
| Net cash used in operating activities | -16,488 | -26,827 |
| Cash paid for ibeo business combination | 0 | 0 |
| Sales of investment securities | 4,286 | 22,402 |
| Purchases of investment securities | 13,552 | 19,326 |
| Purchases of property and equipment | 128 | 307 |
| Net cash used in investing activities | -9,394 | 2,769 |
| Proceeds from stock option exercises | 0 | 0 |
| Principal payments under finance leases | 4 | 6 |
| Principal payments under notes payable | 5,500 | - |
| Net proceeds from issuance of common stock and warrants | 29,979 | 43,289 |
| Net cash provided by financing activities | 24,475 | 43,283 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 150 | 319 |
| Change in cash, cash equivalents, and restricted cash | -1,257 | 19,544 |
| Cash and cash equivalents at beginning of period | 56,247 | - |
| Cash and cash equivalents at end of period | 74,534 | - |
MICROVISION, INC. (MVIS)
MICROVISION, INC. (MVIS)